BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

BeiGene, Ltd. (BGNE) is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.The company currently markets three internally discovered oncology products, including BTK inhibitor, Brukinsa (zanubrutinib), in the United States, China, the EU, the United Kingdom and additional international markets. BeiGene markets its other products like anti-PD-1 antibody, tislelizumab, in the EU and China, and PARP inhibitor, pamiparib, only in ...